ArticleEuropean journal of haematology2026

Real-World Selection of Venetoclax-Obinutuzumab Versus BTK Inhibitor Therapy for Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Rebecca Tidswell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.